The Effect of Whey and Casein on IGFs in Prepubertal Boys
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It is not clear which milk compounds are responsible for the growth stimulation. Through short term intervention studies in prepubertal children, we will test the effects of whey, casein, and milk minerals (especially Ca/P). Outcomes will be IGF-I, IGFBP-3, p-amino acids, oral glucose tolerance test (insulin, glucose, GLP-1 and 2, C-peptide, proinsulin) and markers for bone turn-over in blood and urine (s-osteocalcin, s-bone alkaline phosphatase, urine Dpyr, Ntx) as well as blood pressure.
| Condition | Intervention |
|---|---|
|
Metabolic Syndrome Obesity |
Behavioral: Whey without milk minerals Behavioral: Whey with milk minerals Behavioral: Casein without milk minerals Behavioral: Casein with milk minerals |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | The Effect of Whey and Casein With and Without Milk Minerals on IGFs in Prepubertal Boys |
- IGF-I
- IGFBP-3
- Insulin
- Glucose
- Blood Pressure
- Body Composition
- Adiponectin
- Leptin
- Ghrelin
- C-peptide
- OGGT
- Urea Nitrogen
- Amino Acids
- Osteocalcin
- BAP
- CTX
| Estimated Enrollment: | 60 |
| Study Start Date: | July 2004 |
| Estimated Study Completion Date: | April 2005 |
Milk has evolved to support high growth velocity in newborns and observational and intervention studies suggest that milk has special growth stimulating properties especially regarding body size, bone mass and gut. We have previously shown that a one week high-dose intervention with milk, but not meat, increased fasting IGF-I and insulin levels in prepubertal boys. It is not clear which milk compounds are responsible for the growth stimulation. Through short term intervention studies in prepubertal children, we will test the effects of whey, casein, and milk minerals (especially Ca/P). Outcomes will be IGF-I, IGFBP-3, p-amino acids, oral glucose tolerance test (insulin, glucose, GLP-1 and 2, C-peptide, proinsulin) and markers for bone turn-over in blood and urine (s-osteocalcin, s-bone alkaline phosphatase, urine Dpyr, Ntx) as well as blood pressure. Exploring the growth stimulating effects of these milk components will improve the understanding of dietary effects on growth and bone metabolism, and will be valuable for the diary industry developing dietary products supporting growth e.g. infant formula, products for clinical nutrition and milk based products for nutritional rehabilitation of malnourished children in developing countries.
Eligibility| Ages Eligible for Study: | 8 Years to 8 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- habital milk intake:200 - 500 mL/d
Exclusion Criteria:
- chronic illnesses
- children who suffer from any condition likely to affect their protein metabolism or growth
Contacts and Locations| Denmark | |
| Institute of Human Nutrition, Rolighedsvej 30 | |
| Frederiksberg C, Denmark, 1958 | |
| Study Chair: | Kim F Michaelsen, Dr Med Sci | Institute of Human Nutrition, Rolighedsvej 30, DK-1958 Frederiksberg C, Denmark |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00378820 History of Changes |
| Other Study ID Numbers: | KF 01-072/04, D-111 |
| Study First Received: | September 20, 2006 |
| Last Updated: | January 20, 2009 |
| Health Authority: | Denmark: The Danish National Committee on Biomedical Research Ethics |
Keywords provided by University of Copenhagen:
|
Children Whey Casein Milk minerals |
Growth factors IGF-I Insulin |
Additional relevant MeSH terms:
|
Obesity Metabolic Syndrome X Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Insulin Resistance |
Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Caseins Chelating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013